Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Summary

To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab

Timeline

Start

2017-02-15

Primary completion

2022-02-28

Completion

2022-02-28

Drugs

Indications